Biotech Meets Crypto: ENDRA Life Sciences (NDRA) Stock Skyrockets 33% — Analyst Target $50
ENDRA Life Sciences shares surged 33% to $8.63 midday Oct. 13, 2025, after announcing a $4.9 million crypto-asset treasury placement managed by Arca. The company’s main TAEUS imaging product targets liver fat measurement, with a 250-patient FDA trial underway. Q2 net loss narrowed to $1.2 million, with cash at $1.8 million as of June 30. Analyst coverage is limited; the 12-month price target stands at $50.
